Michael Schlesinger

Title: Michael Schlesinger: Innovator in Cannabinoid Therapeutics

Introduction

Michael Schlesinger is a notable inventor based in Jerusalem, Israel. He has made significant contributions to the field of cannabinoid research, particularly in the development of therapeutic compounds. His work focuses on the medical applications of cannabinoid derivatives, which have the potential to address various health issues.

Latest Patents

Michael Schlesinger holds a patent for "Compositions including quinonoid derivatives of cannabinoids for therapeutic use." This invention relates to cannabinoic quinone compounds, specifically five cannabinoic quinones designated as HU-331, HU-336, HU-345, HU-395, and HU-396. These compounds are described as active agents in pharmaceutical compositions intended for the treatment of inflammatory, infectious, auto-immune, and particularly hyperproliferative disorders. The compounds may serve as anti-tumor agents or for the treatment of cancer. Notably, HU-345, HU-395, and HU-396 are recognized as novel cannabinoic quinones.

Career Highlights

Michael Schlesinger is associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work at this institution has allowed him to explore innovative solutions in cannabinoid therapeutics. His research has the potential to impact the medical field significantly.

Collaborations

Michael has collaborated with prominent figures in the field, including Raphael Mechoulam and Natalya M Kogan. These collaborations have enriched his research and contributed to the advancement of cannabinoid science.

Conclusion

Michael Schlesinger's contributions to cannabinoid therapeutics highlight the importance of innovation in addressing complex health challenges. His work continues to pave the way for new treatments and therapies in the medical field.